French National Academy of Surgery reviews breast cancer care advances

Breast Cancer Care Advances as Specialists Propose Dedicated Surgery Training

Breast cancer treatment is shifting toward more precise, individualized approaches as medical advances in oncology, surgical techniques, and targeted therapies reshape patient care. During Octobre rose, the French National Academy of Surgery reviewed these developments, highlighting how modern diagnostics and tailored therapies aim to reduce unnecessary interventions while improving quality of life.

Medical oncologists and surgeons are adjusting care pathways by analyzing tumor characteristics more closely to evaluate recurrence risks and tailor treatments for each patient, according to Radio VINCI Autoroutes. While traditional approaches relied heavily on standard surgery followed by radiation or chemotherapy, contemporary care integrates biomarkers, genetic mutations, and advanced drug delivery systems.

Conjugated Antibodies and Targeted Immunotherapy Reshape Medical Oncology

Antibody-drug conjugates are transforming systemic treatment by pairing a therapeutic antibody with powerful chemotherapy molecules, as detailed by Xavier Pivot, medical oncologist and general director of the Strauss Institute. In HER2-low breast cancer cases, treatments such as trastuzumab deruxtecan have extended progression-free survival from about five months to nearly ten months, and overall survival from 16.8 to 23.4 months, Actusante.net reported.

For triple-negative breast cancer, which remains particularly challenging to treat, researchers have identified TROP2 as a prominent cellular target. The introduction of sacituzumab govitecan raised response rates to 35%, compared to 5% with standard chemotherapy, according to Actusante.net data. Additionally, researchers are exploring subcutaneous administration methods for antibody-drug conjugates to reduce hospital infusion times to just a few minutes, though high drug concentration requirements present formulation challenges.

Immunotherapy drugs like pembrolizumab and emerging bispecific antibodies—which bind to tumor cells while recruiting immune cells directly to the site—further expand the therapeutic landscape, though high costs remain a significant hurdle.

Surgical Specialization and Minimally Invasive Robotic Techniques

Carole Mathelin, professor of gynecology and obstetrics at the Strasbourg Faculty of Medicine, advocated for establishing a formal breast surgery training path to address institutional complexity. Because the healthcare system maintains only 13 recognized surgical specialties, specialists have worked for years to create a specialized transversal training program in senology designed for gynecologists, digestive surgeons, and plastic surgeons, Univadis reported.

Surgical technologies are also evolving through the use of robotic systems in specialized centers such as Gustave Roussy and Marseille, noted Gilles Houvenaeghel, head of oncological and serological surgery at the Paoli-Calmettes Institute. While robotic assistance facilitates minimally invasive skin-sparing mastectomies with immediate reconstruction, major clinical studies indicate that complication rates remain largely equivalent to traditional open surgery, Univadis reported.

Lipomodeling and Axillary De-Escalation in Breast Reconstruction

Reconstructive techniques increasingly incorporate autologous fat transfer, known as lipomodeling, to avoid the long-term maintenance constraints associated with synthetic implants. Catherine Bouteille, an obstetrician-gynecologist in Saint-Étienne, explained that while the procedure requires patients to have sufficient fat reserves for harvest, it offers a minimally invasive approach using the patient’s own tissue for a more natural result.

Monique Cohen, a senological surgeon at the Bouchard Elsan clinic in Marseille, emphasized the clinical trend toward surgical de-escalation, particularly regarding axillary lymph node dissections. Building on the shift from extensive clearance to sentinel lymph node biopsy, specialists now investigate omitting axillary procedures entirely in selected cases. Concurrently, experimental research explores 3D-printed bio-structures tailored to individual patient anatomy that can be colonized by autologous fat to achieve custom reconstructions.

Frequently Asked Questions

What is an antibody-drug conjugate in breast cancer treatment?

An antibody-drug conjugate combines a targeted therapeutic antibody with chemotherapy molecules to home in on specific proteins on tumor cells while sparing healthy tissue, as reported by Actusante.net.

How does liquid biopsy help monitor breast cancer progression?

Liquid biopsies analyze circulating tumor DNA extracted from a simple blood sample, allowing clinicians to track treatment response, evaluate recurrence risks, and monitor metastatic evolution, according to Radio VINCI Autoroutes.

What is the primary benefit of lipomodeling during breast reconstruction?

Lipomodeling utilizes the patient’s own harvested fat tissue to reconstruct the breast shape, providing a natural alternative that eliminates the need for synthetic implant replacements, Univadis reported.

More on French: French Court Recognizes Flight Attendant's Breast Cancer as Occupational Disease · French Hiking Clubs Launch October Pink Events for Breast Cancer Research